View a 4-part CME video series on assessing for and treating tardive dyskinesia during the COVID-19 pandemic.

Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.

Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”

A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 

A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?

Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych Congress Elevate.

A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.

Psych Congress Steering Committee member Rakesh Jain, MD, MPH, is educating clinicians on the latest research and strategies for treating tardive dyskinesia during the 2020 Psych Congress Regionals meetings. He shares some of his guidance here.

Which of the following is a risk factor for tardive dyskinesia (TD): age, diagnosis of schizophrenia, comorbid bipolar and related disorders, history of extrapyramidal symptoms, or all of these?

    In order to be diagnosed with tardive dyskinesia (TD), a patient must experience involuntary choreifo